Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 76 to 100 of 571

TitleReference numberPublishedLast updated
Otitis media with effusion in under 12sNG233
Ectopic pregnancy and miscarriage: diagnosis and initial managementNG126
Cipaglucosidase alfa with miglustat for treating late-onset Pompe diseaseTA912
Venous thromboembolic diseases: diagnosis, management and thrombophilia testingNG158
Afamelanotide for treating erythropoietic protoporphyriaHST27
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Oesophago-gastric cancer: assessment and management in adultsNG83
Deucravacitinib for treating moderate to severe plaque psoriasisTA907
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA902
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891

Results per page

  1. 10
  2. 25
  3. 50
  4. All